What does the number eleven mean? And what unusual words and expressions incorporate eleven?
The word derives from the Old English endleofan, which means “one left,” as in “one left over ten.”
This literal sense is found in the colloquial expression “the eleventh hour,” which is used to talk about doing something at the last possible moment. For example, “In the eleventh hour, Sophie switched the caterer and invited ten more people to the wedding.”
It’s believed that the expression originally referenced the bible, Matthew 20:1-16. In the parable, laborers were hired at the eleventh hour of a twelve-hour workday. But they received the same wage as workers who began during the first hour.
Is there really a word for a snack eaten at 11 in the morning? In fact, there is. In England, the term “elevenses” refers to a mid-morning snack, such as biscuits with a cup of tea. The Spanish term las onces, “the elevens,” also refers to a refreshment taken around 11.
The word “elevenses” was used in America as well. It referred to the now abandoned custom of a pre-noon whiskey break.
What is the link between a whole bunch of elevens and Veteran’s Day? Read about that here.
Agreements/contracts: Labcyte to use Thermo’s siRNA in Echo plates.
Medical Device Daily September 8, 2011 A Medical Device Daily Staff Report Labcyte (Sunnyvale, California) reported that Thermo Fisher Scientific (Waltham, Massachusetts) is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo qualified source plates. This format enables customers to use the Echo liquid handler to transfer RNAi reagents during experiments, eliminating manual handling, reducing volumes, lowering costs and decreasing the risk of contamination.
The Echo liquid handler, used in scientific research and drug discovery, uses acoustic energy to move fluids without physical contact with the sample. There are no pipette tips, pin tools or nozzles involved. This “touchless” dispensing eliminates the possibility of contaminating the RNAi stocks and allows for easy preparation of assay-ready plates. It also reduces costs associated with laboratory consumables and reduces labor by making the process more efficient, the company said. see here north kansas city hospital
“Our revolutionary instruments allow users to significantly lower transfer volumes, leading to dramatic reductions in cost,” said Mark Fischer-Colbrie, president/CEO of Labcyte. “Researchers show that low-volume siRNA transfections using acoustic transfer are equal or superior to those obtained with traditional liquid handlers. Cross-contamination is eliminated and transfection rates improve. Costs are further reduced with the elimination of disposable pipettes.” Labcyte specializes in liquid handling. Echo liquid handling systems use sound to precisely transfer liquids. Labcyte claims the Echo platform generates better results with significantly lower costs when compared to traditional liquid handling systems that have high running costs, are prone to transfer errors, risk sample contamination and waste large amounts of plastic lab consumables.
In other agreements/contracts * Coventry Health Care of Kansas (Wichita) reported the addition of North Kansas City Hospital (Kansas City, Missouri) into its provider network. The multi-year contract includes physicians in the affiliated practices of Meritas Health Corporation.
“All of us at North Kansas City Hospital are pleased with this partnership,” said David Carpenter, North Kansas City Hospital’s president/CEO. “We stand ready to care for Coventry’s members, especially those who call the Northland ‘home.’” Michael Murphy, Coventry’s president/CEO, said, “Coventry prides itself on having an extensive provider network. We are very pleased to welcome North Kansas City Hospital and their physicians back into our family of providers serving our members and clients in the Northland.” Coventry Health Care is a managed healthcare company which operates health plans, insurance companies, network rental and workers’ compensation services companies.
* GE Healthcare (Chalfont, UK) and KC BioMedix (Laurel, Maryland) reported an agreement that grants GE Healthcare’s Maternal Infant Care division (MIC) exclusive rights for distribution and marketing of the KC BioMedix NTrainer pulsatile neurostimulation system.
There are over 500,000 infants born prematurely in the U.S. each year, and as many as 50% are suffering from the inability to breast or bottle feed. Because hospitals are reluctant to discharge these patients from the neonatal ICU until they achieve 100% oral feeding competency, there is an important opportunity to improve the emotional, medical, and economic impact for patients and their families, along with hospitals and insurers. The NTrainer System incorporates a pulsating pacifier and reinforces nonnutritive suck (NNS) in infants and then measures the progress of their ability to suck. in our site north kansas city hospital
Clinically, the NTrainer enables neonatal caregivers the ability to better manage incompetent feeding in neonates by providing a standardized assessment tool to measure NNS performance. NNS is an essential neurological building block in an infant’s coordination of sucking, swallowing and breathing u a capability required for independent oral feeding and the development of a healthy baby.
* TrovaGene (San Diego), a maker of transrenal molecular diagnostics to facilitate personalized medicine, has signed a license for an assay that detects Hairy Cell Leukemia (HCL).
A recent discovery, published in the June 16 New England Journal of Medicine by Brunangelo Falini, MD, and colleagues, showed that a specific mutation in the BRAF gene was present in all patients with HCL in the study. TrovaGene holds exclusive rights to the discovery and will offer nonexclusive licenses for its diagnostic application. The results of such a test will also help physicians to monitor effectiveness of treatment and disease relapse.
HCL is a cancer of the bone marrow resulting in accumulation of abnormal B lymphocytes in the blood. There are about 2,000 new cases of HCL diagnosed annually in the U.S. and Europe. Most patients are successfully treated with cladribine or pentostatin with 80% of patients achieving a complete response. Patients who relapse often respond successfully to retreatment. Monitoring for relapse is typically performed by routine complete blood count but may include bone marrow testing. The name stems from the hairy appearance of the abnormal B lymphocytes under a microscope, visible in about 85% of HCL cases.
February 28, 2014 20
Back to Top